Drug Company Sales Reps In India Say Firms Overcharge At Will (India)
This article was originally published in PharmAsia News
Executive SummaryAn organization representing a quarter of drug company sales representatives in India accuse the firms of arbitrarily increasing the prices of their products and getting away with it. The Federation of Medical and Sales Representatives' Associations of India made the accusations in notes to leading members of Parliament. The FMRAI said some companies have hiked their prices by as much as 100 times beyond the government-ordered price caps. Some essential or popular medicines have increased by 600 percent over the past nine years, said FMRAI's joint general secretary, who called the recent voluntary price reduction a "great hoax." Authorities have tried to recover some of the alleged overcharges, but drug companies have filed 75 court challenges against the efforts. (Click here for more ) "Medical Reps Accuse Drug Firms Of Overcharging" Business Standard (India) (12/10/07)
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.